These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
569 related articles for article (PubMed ID: 9635698)
1. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698 [TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
4. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471 [TBL] [Abstract][Full Text] [Related]
5. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891 [TBL] [Abstract][Full Text] [Related]
7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929 [TBL] [Abstract][Full Text] [Related]
8. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498 [TBL] [Abstract][Full Text] [Related]
9. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358 [TBL] [Abstract][Full Text] [Related]
10. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788 [TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer. Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592 [TBL] [Abstract][Full Text] [Related]
13. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Vicini FA; Kestin LL; Martinez AA Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815 [TBL] [Abstract][Full Text] [Related]
14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788 [TBL] [Abstract][Full Text] [Related]
15. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839 [TBL] [Abstract][Full Text] [Related]
16. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379 [TBL] [Abstract][Full Text] [Related]
17. High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. Chiang PH; Fang FM; Jong WC; Yu TJ; Chuang YC; Wang HJ Int J Urol; 2004 Mar; 11(3):152-8. PubMed ID: 15009363 [TBL] [Abstract][Full Text] [Related]
18. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial. Dinges S; Deger S; Koswig S; Boehmer D; Schnorr D; Wiegel T; Loening SA; Dietel M; Hinkelbein W; Budach V Radiother Oncol; 1998 Aug; 48(2):197-202. PubMed ID: 9783892 [TBL] [Abstract][Full Text] [Related]
19. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828 [TBL] [Abstract][Full Text] [Related]